Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs
Sam Zeraatian1, Abbas Salehiomran2, Ruhollah Mehdinavaz Aghdam2, Seyed Hossein Ahmadi Tafti1*, Seyed Reza Ghiasi3, Nasim Kiaee2,Shahram Rabbani2, Ali Ghiasedin4, Hanif Tabesh5, Nazafarin Kamalzade6 and Laurie Anne Walden7
- *Corresponding Author:
- Seyed Hossein Ahmadi Tafti
M.D, Department of Cardiovascular Surgery
Tehran Heart Center (THC), Tehran University
of Medical Sciences (TUMS), Tehran, Iran
E-mail: [email protected] yahoo.com
Received date: July 26, 2015; Accepted date: October 07, 2015; Published date: October 15, 2015
Citation: Zeraatian S, Salehiomran A, Aghdam RM, Tafti SHA, Ghiasi SR (2015) Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs. Cardiol Pharmacol 4:159. doi:10.4172/2329-6607.1000159
Copyright: © 2015 Zeraatian S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims: Glucagon-like peptide 1 (GLP-1) is one of the new choices in the management of diabetes mellitus because of its glucose regulatory effects. GLP-1 receptors are expressed not only in islet cells, kidney, lung, brain, and gastrointestinal tract, but also in the heart. The cardiac effects of GLP-1 play a major role in the choice to use this treatment, considering the expression of GLP-1 receptors in heart. Degradation by dipeptidyl peptidase-IV (DPPIV) makes GLP-1’s half-life very short. In this study, the cardiac effects of GLP-1 with chitosan-based scaffold as well as the tissue changes after induction of myocardial infarction in canines were evaluated.
Method: Twelve canines of a similar breed and weight were included in this study. They were categorized into three groups: A case group treated with GLP-1 based on a chitosan scaffold, a group given chitosan with normal saline, and a control group given normal saline alone. Every four weeks after induction of infarction, the troponin-I serum level, regional wall motion abnormality (RWMA), angiogenesis, and microscopic and macroscopic tissue changes were analyzed.
Results: Angiogenesis and infarcted area thickness (which is inversely related to the subsequent risk of pseudoaneurysm development) were significantly higher in the case group compared with the other two groups (p value<0.05). Our case group recorded lower scores of RWMA compared with other canines (p value=0.02).
Conclusion: This investigation revealed that the new compound (GLP-1+chitosan) not only lengthens the releasing duration of GLP-1 but also has cardioprotective effects after myocardial infarction.